CTRI/2020/07/026535已完成未知
A randomized open label parallel group trial to study the safety and efficacy of steam impregnated with 8.4 % Sodium Bicarbonate in patients with Covid-19 infection
Dr Bharat S Mody0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Males and Females of age 18 years or more diagnosed with Covid-19 infection by RT-PCR test method and not on Invasive Ventilatory Support.
- •Subject willing to give written consent (Volunteer Information Sheet and Informed Consent Form) prior to enrolment in the study.
- •Subjects must have clinically acceptable results for all the screening parameters.
排除标准
- •Males and Females not proven to have Covid-19 infection by a positive RT-PCR test result.
- •Males and Females having proven Covid-19 infection by positive RT-PCR test result but on Invasive Ventilatory Support.
- •Subject deemed uncooperative or noncompliant.
研究者
相似试验
已完成
不适用
A randomized open-label parallel-group trial to evaluate the efficacies of step-up and step-down therapies using budesonide/formoterol combination (160/4.5 mcg) in patients with poorly controlled asthma even after inhaled corticosteroid therapybronchial asthmaJPRN-UMIN000008912Kinki Respiratory and Allergy Diseases Research Group100
已完成
Unknown
A prospective study to explore the effect on work productivity when strengthening exercise therapy in patients with chronic low back paichronic low back painJPRN-UMIN000041037Shionogi & Co., Ltd.101
招募中
不适用
Open-label, randomized parallel group trial on the efficacy and safety of intra-articular administration of bevacizumab for knee osteoarthritis.Osteoarthritis of knee jointsJPRN-UMIN000008260ational Hospital Organization Sagamihara Hospital100
已完成
不适用
A clinical study to study the effect of a herbal formulation in patients with diarrhoea in comparison with oral rehydration therapyCTRI/2018/03/012699Clinfound Clinical Research Services PvtLtd100
进行中（未招募）
1 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)portal hypertensionMedDRA version: 20.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-005171-40-ATBoehringer-Ingelheim RCV GmbH & Co KG80